vaccines

The world’s first participants to take part in a phase III trial of the Novavax COVID-19 vaccine candidate have  been recruited at one of the new NIHR National Patient Recruitment Centres (NPRC) based in Blackpool, UK. US-based biotechnology firm, Novavax, launched the phase III clinical trial of a potential COVID-19 vaccine, NVX-CoV2373, in the UK […]

Cobra Biologics is to manufacture Scancell Holdings COVID-19 vaccine. The agreement covers Good Manufacturing Practice (GMP) production of plasmid DNA needed to generate the DNA vaccine, against SARS-CoV-2, for use in a Phase I clinical trial in 2021 (COVIDITY). The project is funded by an Innovate UK grant awarded to the consortium between Scancell, the […]

What a time to be involved in drug discovery. While COVID-19 has of course created unprecedented conditions on a global scale, it has also highlighted the extent to which this sector offers depth of knowledge, skill and innovation. It is a pleasure to learn more about the market – both COVID and non-COVID – and […]

A fifth (22%) of people have said that when a COVID-19 vaccine is approved, they’re unlikely to get it, with 10% of people saying they were ‘very unlikely’ to get vaccinated, find UCL researchers as part of the COVID-19 Social Study. Only half (49%) of people reported being ‘very likely’ to get vaccinated. Vaccine myths […]

With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward.  It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect them. COVID-19 has created an immense global effort centred […]

Laural Barchas, Senior Technical Writer, Takara Bio, looks at the work behind the creation of a COVID-19 vaccine and outlines the input of Takara Bio in the process We are at a decisive moment in history. With the rise of the novel coronavirus SARS-CoV-2 and its devastating toll, the scientific and medical communities must act […]